167 related articles for article (PubMed ID: 26363225)
1. Breast cancer cells: Modulation by melatonin and the ubiquitin-proteasome system--a review.
Vriend J; Reiter RJ
Mol Cell Endocrinol; 2015 Dec; 417():1-9. PubMed ID: 26363225
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
Yi X; Wei W; Wang SY; Du ZY; Xu YJ; Yu XD
Biochem Pharmacol; 2008 May; 75(9):1697-705. PubMed ID: 18342836
[TBL] [Abstract][Full Text] [Related]
3. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
4. The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation.
Zhu J; Zhao C; Kharman-Biz A; Zhuang T; Jonsson P; Liang N; Williams C; Lin CY; Qiao Y; Zendehdel K; Strömblad S; Treuter E; Dahlman-Wright K
Oncogene; 2014 Aug; 33(34):4340-51. PubMed ID: 24441041
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
[TBL] [Abstract][Full Text] [Related]
6. Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader.
Zhao Y; Zhao C; Lu J; Wu J; Li C; Hu Z; Tian W; Yang L; Xiang J; Zhou H; Deng Z; Huang J; Hong K
Pharmacol Res; 2019 Aug; 146():104294. PubMed ID: 31175940
[TBL] [Abstract][Full Text] [Related]
7. RNF8 identified as a co-activator of estrogen receptor α promotes cell growth in breast cancer.
Wang S; Luo H; Wang C; Sun H; Sun G; Sun N; Zeng K; Song H; Zou R; Zhou T; Cong R; Liu W; Yang L; Li D; Zhou X; Zhong X; Lin L; Jiao J; Yan G; Wang X; Min X; Cao L; Zhao Y
Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1615-1628. PubMed ID: 28216286
[TBL] [Abstract][Full Text] [Related]
8. FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1.
Liu Y; Ao X; Jia Z; Bai XY; Xu Z; Hu G; Jiang X; Chen M; Wu H
Sci Rep; 2015 Mar; 5():8796. PubMed ID: 25740706
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of HTLV-1 Tax oncoprotein on the different estrogen-induced-ER α-mediated transcriptional activities.
Abou-Kandil A; Eisa N; Jabareen A; Huleihel M
Cell Cycle; 2016 Oct; 15(19):2626-2635. PubMed ID: 27420286
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.
Prenzel T; Begus-Nahrmann Y; Kramer F; Hennion M; Hsu C; Gorsler T; Hintermair C; Eick D; Kremmer E; Simons M; Beissbarth T; Johnsen SA
Cancer Res; 2011 Sep; 71(17):5739-53. PubMed ID: 21862633
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis.
Ramamoorthy S; Tufail R; Hokayem JE; Jorda M; Zhao W; Reis Z; Nawaz Z
Breast Cancer Res Treat; 2012 Feb; 132(1):97-108. PubMed ID: 21553290
[TBL] [Abstract][Full Text] [Related]
12. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.
Nathan S; Ma Y; Tomita YA; De Oliveira E; Brown ML; Rosen EM
Breast Cancer Res Treat; 2017 Dec; 166(3):681-693. PubMed ID: 28808806
[TBL] [Abstract][Full Text] [Related]
13. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells.
Kiefer T; Ram PT; Yuan L; Hill SM
Breast Cancer Res Treat; 2002 Jan; 71(1):37-45. PubMed ID: 11859872
[TBL] [Abstract][Full Text] [Related]
14. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer.
Johnsen SA; Güngör C; Prenzel T; Riethdorf S; Riethdorf L; Taniguchi-Ishigaki N; Rau T; Tursun B; Furlow JD; Sauter G; Scheffner M; Pantel K; Gannon F; Bach I
Cancer Res; 2009 Jan; 69(1):128-36. PubMed ID: 19117995
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Wang C; Fan S; Li Z; Fu M; Rao M; Ma Y; Lisanti MP; Albanese C; Katzenellenbogen BS; Kushner PJ; Weber B; Rosen EM; Pestell RG
Cancer Res; 2005 Aug; 65(15):6557-67. PubMed ID: 16061635
[TBL] [Abstract][Full Text] [Related]
16. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
Fan M; Bigsby RM; Nephew KP
Mol Endocrinol; 2003 Mar; 17(3):356-65. PubMed ID: 12554766
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
18. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
19. Effect of TPA and HTLV-1 Tax on BRCA1 and ERE controlled genes expression.
Jabareen A; Abu-Jaafar A; Abou-Kandil A; Huleihel M
Cell Cycle; 2017 Jul; 16(14):1336-1344. PubMed ID: 28594273
[TBL] [Abstract][Full Text] [Related]
20. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
